Home Business Ripple Therapeutics Announces Collaboration and Option-to-License Agreement with AbbVie to Develop Next-Generation...

Business

Ripple Therapeutics Announces Collaboration and Option-to-License Agreement with AbbVie to Develop Next-Generation Therapies for Glaucoma Management

Editor

September 18, 2024

219

Ripple Therapeutics today announced a collaboration and option-to-license agreement with AbbVie to develop RTC-620, a next generation, fully biodegradable, sustained release drug delivery intracameral implant with repeat dosing capabilities to reduce intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT…

Get $10 by answering a Simple Survey. Click Here

Ripple Therapeutics Announces Collaboration and Option-to-License Agreement with AbbVie to Develop Next-Generation Therapies for Glaucoma Management

Company

Latest

IEEMA Strengthens Southern Presence; Launches Telangana Power Conclave to Boost Electrical and Electronics Manufacturing Industry

PFRDA constitutes Committee for Strategic Asset Allocation and Risk Governance (SAARG)

Actor Pulkit Samrat shares his life story and film industry experience with students at the Under25 Summit At Campus at VIT

Popular

IEEMA Strengthens Southern Presence; Launches Telangana Power Conclave to Boost Electrical and Electronics Manufacturing Industry

PFRDA constitutes Committee for Strategic Asset Allocation and Risk Governance (SAARG)

Actor Pulkit Samrat shares his life story and film industry experience with students at the Under25 Summit At Campus at VIT

Sitemap